Alzinova

1.64 SEK

+3.80 %

Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+3.80 %

+27.33 %

+31.62 %

-3.76 %

-52.60 %

-55.19 %

-28.95 %

-67.40 %

-77.13 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Market cap

171.09M SEK

Turnover

273.09K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2

2026

Annual report '25

All

Press releases

3rd party

ShowingAll content types

Press release12/9/2025, 11:25 AM

BioStock: Alzinova comments on the Letter of Intent in Saudi Arabia

Press release12/5/2025, 10:09 AM

BioStock: Alzinova signs Letter of Intent with Saudi Arabian stakeholder

Press release12/4/2025, 12:46 PM

DNB Carnegie Access: Alzinova: Memorandum of Understanding for commercial partnership in Saudi Arabia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/4/2025, 10:00 AM

Alzinova enters memorandum of understanding for commercial partnership

Press release11/13/2025, 5:24 PM

Redeye: Alzinova (Q3 review) - Regulatory progress in anticipation of a deal

Press release11/13/2025, 5:18 PM

DNB Carnegie Access: Alzinova: Progress hinges on partnership execution – Q3 review

Press release11/13/2025, 1:07 PM

BioStock: FDA approval and strong data position Alzinova ahead of Phase II

Regulatory press release11/13/2025, 6:45 AM

Alzinova publishes interim report for January – September 2025

Press release11/11/2025, 1:39 PM

Alzinova to participate at CTAD 2025 with two presentations on ALZ-101

Press release10/20/2025, 8:23 AM

BioStock: Alzinova secures short-term financing – CEO comments

Press release10/16/2025, 8:49 AM

DNB Carnegie Access: Alzinova: Secures short-term loan

Regulatory press release10/15/2025, 9:48 PM

Alzinova enters into SEK 11 million short-term loan arrangement to secure its working capital needs

Press release10/7/2025, 8:01 AM

BioStock: Alzinova comments on the FDA Fast Track Designation

Press release10/6/2025, 6:38 AM

DNB Carnegie Access: Alzinova: FDA clears ALZ-101 for Fast Track

Regulatory press release10/4/2025, 8:45 AM

Alzinova Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer’s Disease

Press release9/25/2025, 9:42 AM

BioStock: Video from Alzinova's presentation at BioStock Investing in Life Science – From Seed to Success

Press release9/5/2025, 10:58 AM

BioStock: Alzinova comments on FDA approval ahead of Phase II

Regulatory press release9/4/2025, 10:30 AM

Alzinova Receives FDA (IND) Approval for Phase II Study of ALZ-101 in Alzheimer’s Disease

Press release9/2/2025, 2:51 PM

DNB Carnegie Access: Alzinova: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Press release8/29/2025, 6:45 AM

Alzinova participates in several industry and investor events during autumn 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.